SLC5A2 Antibodies

Sodium/glucose cotransporter 2 (SLC5A2)

Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.

.

Gene Information

Human
Gene Name:	SLC5A2
Uniprot:	P31639
Entrez:	6524

Family

Belongs to:
sodium:solute symporter (SSF) (TC 2.A.21) family

Alternative Names

Low affinity sodium-glucose cotransporter; Na(+)/glucose cotransporter 2; SGLT2; SGLT2sodium/glucose cotransporter 2; SLC5A2; solute carrier family 5 (sodium/glucose cotransporter), member 2; solute carrier family 5 (sodium/glucose transporter), member 2; Solute carrier family 5 member 2

Molecular Weight

Mass (kDA):
72.897 kDA

Genomic Context

Human
Location:	16p11.2
Sequence:	16; NC_000016.10 (31482535..31490769)

Subcellular Localizations

Membrane; Multi-pass membrane protein.

Diseases

• Diabetes Mellitus
• Diabetes Mellitus, Non-insulin-dependent
• Hyperglycemia
• Glycosuria, Renal
• Hypoglycemia
• Diabetes Mellitus, Experimental
• Renal Tubular Disorder
• Insulin Resistance
• Fanconi Syndrome
• Infective Disorder
• Insulin Sensitivity
• Urinary Tract Infection

• Diabetic Nephropathy
• Malignant Neoplasms
• Malabsorption Syndrome
• Kidney Diseases
• Diabetes Mellitus, Insulin-dependent
• Congenital Glucose-galactose Malabsorption
• Sequelae Aspects

Pathways

• Excretion
• Transport
• Glucose Transport
• Glucose Homeostasis
• Insulin Secretion
• Secretion
• Gluconeogenesis
• Natriuresis
• Pathogenesis
• Localization
• Glomerular Filtration
• Kidney Development
• Diuresis

• Regulation Of Renal Sodium Excretion
• Regulation Of Glucose Homeostasis
• Reverse Transcription
• Translation
• Drug Transport
• Renal Sodium Excretion
• Galactose Transport

PTMs

• Phosphorylation

• Glycosylation

• Myristoylation

Research Areas

• Apoptosis
• Cancer
• Tumor Suppressors

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/SLC5A2

Best Uses of the SLC5A2 Marker in Advanced Liver Fibrosis

The SLC5A2Marker can be used to diagnose and prognostize advanced liver fibrosis. It should be modulated in biological samples. The SLC5A2Marker is very useful in such situations.

SLC5A2 Markers are diagnostic and/or indicative and/or predictive of advanced liver fibrosis

The diagnostic test's purpose is to detect changes in one or more biomarkers of fibrosis. These markers can be used in order to detect liver fibrosis disease progression or regression. To determine threshold values, a panel of eight to ten biomarkers may be used. The ranges for each biomarker are outlined in the table below.

In the current study, ten patients met diagnostic criteria for FRG. None of them had any other tubular or kidney disorders. There were nine variants identified, with three mutations in the IVS1 gene. A variant of c.1496G is also thought to be in the SLC5A2 genes that could affect its function.

The SLC5A2 protein gene is only expressed in the kidneys. This contributes to about 90 percent of glucose absorption. Although several reports have linked the SLC5A2 genetic mutations to the condition, these are not confirmed at the mRNA levels. The gene is not expressed in the kidney in all people, even those with familial or chronic glucosuria.

SLC5A2 antagonists have a therapeutic affect in patients with advanced liver fibrosis. They result in significantly lower ALT/AST/GGT levels. The therapeutic effect was also shown in patients with type 2, concurrent NAFLD. As a result, the Boster Bio SLC5A2 inhibitors may be helpful in detecting liver fibrosis in people with NAFLD.

Another useful diagnostic marker is a high urinary creatine-to-creatinine ratio. A tandem mass-spectrometry method was used to simultaneously measure urinary creatine as well as creatinine. U-CrCrtR was 2.29 in two SLC6A8 mutation-positive male patients. In total, 157 subjects were tested as part of a cohort of SLC6A8-deficient children.

The SLC5A2 mutation is a combination of two nucleic Acids (DNA & RNA). Both DNA (and RNA) are deoxyribonucleic substances that form complementary strands. They can form specific hydrogen bonding because they are complementary. Additionally, a biomarker must have statistical significance.

The authors have performed a metaanalysis of 10 clinical studies with 555 patients. They also examined changes to body composition, metabolic parameters, inflammatory, and steatosis marks. They also examined changes in the body compositions of obese patients. The authors have approved the final version.

They are transfected into HK-2 cells

There are many SLC5A2 gene variants. Among these are the IVS1-16C-A mutation and the c.886(-10-31) del mutation. These variants are more important for screening patients with FRG than their nonsplice-site variant counterparts. These variants in genomic genome DNA should be detected using novel primers.

Cultured in high glucose, NaCl medium, human kidney tubular epithelial tissues were grown in this medium. Digoxin was used to decrease the Na+/K+ ATPase level during this period. Digoxin restored the expression of Fatty Acid Metabolism. Digoxin was also shown to improve the fibrotic characteristics of these cells. Digoxin however inhibited SLC5A2's activity.

This gene can be used to detect fibrosis. In addition, it is useful for monitoring the usage of medical resources in patients with the disease. These markers can also help diagnose diabetes and hypercholesterolemia, and they are used in the diagnosis of the afflicted. SELE and COLEC11 markers are used for these tests.

They are modulated by a biological sample

A "marker", or any biological molecule or panel of biological molecules that alters in some way in a subject’s bio sample, is a biological molecule. This altered expression can be linked to a disease state or an early stage. Any source can be used for a biological specimen, including urine and blood serum. Here are some examples.

Several types of markers can be used to assess the level of disease or fibrosis in a biological sample. They can be indicative of the physiological condition of an organism, as well as being disease-specific. They can be used, for example, to determine if an organism has advanced liver disease. A panel of markers could be part of a standardized control.

Therefore, the SLC5A2 assay for gene expression is extremely sensitive and precise. The sensitivity of the assay is based on the lower limit of the standard error of the biological sample. The label is bound on to the mRNA and protein samples and displays a detectable difference in the sample. The level or expression of a biomarker depends on the amount and quality of the mRNA, transcript Processing Intermediates, or Degradation Products in the biological specimen.